Zynerba Pharmaceuticals Inc. allegedly misled investors about financial aspects of its proposed merger with Harmony Biosciences Holdings Inc., a shareholder suit says.
The company and its directors allegedly omitted or misrepresented key information ahead of the merger, including details about the sales process and conflicts of interest for management, financial projections, and data underlying the deal’s valuation, according to a complaint filed in US District Court for the Eastern District of Pennsylvania.
The deal that the companies announced on Aug. 14 includes a nearly $1.11 cash per share consideration for equity shares and $2.54 for non-tradeable contingent value rights ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.